Screening of novel VEGFR-2-targeting sesquiterpenes from Lindera aggregata and anti-angiogenesis assay
Bioorganic Chemistry · 2026-03 · 170 · 109443
DOI: 10.1016/j.bioorg.2025.109443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-03. Verfasst von Wenhui Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Ti…. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Sesquiterpenes, Angiogenesis Inhibitors, Lindera. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Overseas Expertise Introduction Center for Discipline Innovation of Food Nutrition and Human Health, NSFC.
Abstract (Originalsprache)
As one of the key secondary metabolites from plants, sesquiterpenoids exhibit significant promise for treating various diseases owing to their extensive structural diversity and remarkable pharmacological activities. In recent years, vascular endothelial growth factor receptor 2 (VEGFR-2) has attracted considerable interest as a critical target for anticancer drug development. This study conducted a systematic chemical analysis of Lindera aggregata (Sims) Kosterm. (Lauraceae), a species rich in sesquiterpenoid constituents. Of the 14 sesquiterpenoids that were isolated, compounds 1-8 were found to be undescribed. The results of affinity ultrafiltration mass spectrometry (AUF-MS) screening suggested that compounds 1, 3, 4, 6, and 12-14 demonstrated binding affinity for VEGFR-2. Further molecular docking simulation revealed that the binding free energies of these compounds with VEGFR-2 (PDB ID: 2OH4) ranged from -7.2 to -8.2 kcal/mol, suggesting their potential anti-angiogenesis activity. Subsequent evaluation demonstrated the angiogenesis inhibitory effects of compound 3in vivo and in vitro. This research provided a theoretical foundation for screening natural products with anti-tumor activity and identified potential lead compounds for developing novel anticancer drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, PR China.
- College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, PR China. Electronic address: xujing611@nankai.edu.cn.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, PR China. Electronic address: victgyq@nankai.edu.cn.
Förderung
- Overseas Expertise Introduction Center for Discipline Innovation of Food Nutrition and Human Health
- NSFC
Zitieren
APA
Liu, W., Jiang, H., Guo, C., Jin, X., Lee, D., Xu, J., & Guo, Y. (2026). Screening of novel VEGFR-2-targeting sesquiterpenes from Lindera aggregata and anti-angiogenesis assay. Bioorganic Chemistry, 170, 109443. https://doi.org/10.1016/j.bioorg.2025.109443
Vancouver
Liu W, Jiang H, Guo C, Jin X, Lee D, Xu J, et al. Screening of novel VEGFR-2-targeting sesquiterpenes from Lindera aggregata and anti-angiogenesis assay. Bioorganic Chemistry. 2026;170:109443. doi:10.1016/j.bioorg.2025.109443
BibTeX
@article{Liu2026,
author = {Liu, Wenhui and Jiang, Haojing and Guo, Caixia and Jin, Xiaomeng and Lee, Dongho and Xu, Jing and Guo, Yuanqiang},
title = {Screening of novel VEGFR-2-targeting sesquiterpenes from Lindera aggregata and anti-angiogenesis assay},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {170},
pages = {109443},
doi = {10.1016/j.bioorg.2025.109443}
}
EUVIMED